Importantly, the combination of HE4, with any of the three markers, led to an increased accuracy compared to either individual marker alone (summarized in Table 5), suggesting the potential clinical usage of HE4 in pancreatic adenocarcinoma. The gene discussed is WFDC2; the disease is pancreatic adenocarcinoma.